A previous study has shown that upregulation of receptor tyrosine kinase AXL or downstream targets of AXL and PI3K/mTOR pathways were the strongest markers of resistance to Adavosertib identified in the proteome of a resistant small cell lung carcinoma (SCLC) cell line (Sen et al., 2017). This evidence concerns the gene NTRK1 and small cell lung carcinoma.